Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Neotrail Therapeutics Inc. currently maintains 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This volume of activity suggests a targeted approach to their intellectual property, likely focusing on a specific biological discovery. The concentration of efforts in the Biotechnology & Pharmaceuticals sector indicates that the company's current legal strategy is centered on this technical domain.
The prosecution is managed by 1 distinct examiner and 1 distinct art unit, ensuring a highly focused examination environment. This alignment between 1 distinct examiner and 1 distinct art unit allows for a consistent dialogue between the applicant and the USPTO, as there are no conflicting viewpoints from other examiners. The presence of 1 distinct art unit suggests that the technology is classified within a specific and well-defined technical niche.
CHEN, STACY BROWN is the busiest examiner for this portfolio, currently handling 1 busiest examiner pending action. As the examiner assigned to the company's active matter, CHEN, STACY BROWN will determine the immediate success of the prosecution. Practitioners should review the examiner's history within the Biotechnology & Pharmaceuticals field to better anticipate potential rejections for the 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHEN, STACY BROWN | 1 | 66.1% | +40.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17928098 | CANCER TREATMENT STRATEGIES USING ARENAVIRUS VECTORS | CHEN, STACY BROWN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17928098 | CANCER TREATMENT STRATEGIES USING ARENAVIRUS VECTORS | CHEN, STACY BROWN | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17928098 | CANCER TREATMENT STRATEGIES USING ARENAVIRUS VECTORS | CHEN, STACY BROWN | 1671 | §102§103§112Other | Non-Final OA | — | Pending | Nov 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNeotrail Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Stacy Brown Chen has the most, with 1 of Neotrail Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
